24 In May 2013 Ranbaxy also pleaded guilty to felony charges in the US relating

24 in may 2013 ranbaxy also pleaded guilty to felony

This preview shows page 10 - 11 out of 32 pages.

24 In May 2013, Ranbaxy also pleaded guilty to felony charges in the US, relating to the manufacture and distribution of certain adulterated drugs made at Ranbaxy’s manufacturing facilities in India and had to pay a fine of USD 500 million. 25 Further, in September 2013, the company’s Mohali facility was also banned from manufacturing pharmaceuticals which were intended to be exported to the US. 26 This was followed by the ban on the Toansa facility in Punjab for lapses in quality control and adherence to procedure. 27 C. Daiichi Daiichi is a global pharmaceutical company with corporate origin in Japan. 28 In 2008, Daiichi acquired a controlling stake in Ranbaxy. However, the value of Daiichi’s investments has halved over the years, as Ranbaxy has not been able to ensure compliance of its factories supplying to the US, with USFDA guidelines. 29 22. For more information regarding the acquisition of controlling stake by Daiichi in Ranbaxy, please refer to our M&A Lab at . com/information/navigation/navigation2/ma-lab/ma-lab/article/ranbaxy-daiichi-deal-dissected.html, last accessed on June 24, 2014 23. , last accessed on June 24, 2014 24. , last accessed on June 24, 2014 25. , last accessed on June 24, 2014 26. , last accessed on June 24, 2014 27. , last accessed on June 24, 2014 28. , last accessed on June 24, 2014 29. 30. , last accessed on June 24, 2014 31. - ranbaxy-deal/articleshow/34992210.cms, last accessed on June 24, 2014 II. Deal Snapshot Merging Company Ranbaxy Surviving Company Sun Pharma Share Swap Ratio 0.8 share of Sun Pharma of face value of INR 1/- each will be allotted to the shareholders of Ranbaxy for each share of INR 5/- each held by them in Ranbaxy. Implied value per share INR 457 for each Ranbaxy share, representing an 18 percent premium to Ranbaxy’s 30-day volume weighted average share price 30 Total equity value of the Transaction USD 3.2 billion (USD 4 billion including payment to NCD holders) A brief chronology of events pertaining to the Transaction is provided below: Date Event April 6, 2014 Resolutions regarding the amalgamation agreement and other matters passed at the Board of Directors meetings of Sun Pharma and Ranbaxy April 30, 2014 Andhra Pradesh High Court issues notices to the Securities and Exchange Board of India (“ SEBI ”),
Image of page 10
Image of page 11

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture